Incyte Corporation (LON:0J9P)
London
· Delayed Price · Currency is GBP · Price in USD 70.10
-0.27 (-0.39%)
At close: Jun 11, 2025
Incyte Employees
Incyte had 2,617 employees as of December 31, 2024. The number of employees increased by 93 or 3.68% compared to the previous year.
Employees
2,617
Change (1Y)
93
Growth (1Y)
3.68%
Revenue / Employee
1.31M GBP
Profits / Employee
6.29K GBP
Market Cap
9.84B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| HUTCHMED (China) | 1,811 |
| Genus | 3,500 |
Incyte News
- 5 days ago - Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 8 days ago - Incyte rises as it will present new data on thrombocythemia asset at conference - Seeking Alpha
- 8 days ago - Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025 - Business Wire
- 9 days ago - 20 stocks primed for rapid growth while trading at half of Nvidia's valuation - Market Watch
- 13 days ago - Incyte: Good Company, But Potentially Overvalued Given Patent Cliffs - Seeking Alpha
- 15 days ago - Incyte to Present at Upcoming Investor Conference - Business Wire
- 27 days ago - Incyte gets expanded FDA approval for Zynyz in anal cancer - Seeking Alpha
- 27 days ago - Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States - Business Wire